Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The objective of this randomized clinical trial is to investigate whether transcutaneous auricular vagus nerve stimulation (taVNS) can improve the recovery of patients undergoing coronary artery bypass grafting (CABG) through autonomic modulation, while also evaluating the safety of the intervention.
The main questions this study aims to answer are:
Participants will:
Full description
Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide. Coronary artery bypass grafting (CABG) is frequently indicated in patients with advanced disease. However, the postoperative period is associated with autonomic dysfunction, characterized by increased sympathetic activity and reduced vagal tone, which may contribute to cardiovascular complications and prolonged recovery.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive technique that involves electrical stimulation of the auricular branch of the vagus nerve. By modulating autonomic activity, taVNS may represent a complementary approach to supporting postoperative recovery. However, evidence regarding its application in the immediate postoperative period following CABG remains limited.
This randomized controlled clinical trial aims to investigate the effects of taVNS on autonomic modulation in patients undergoing CABG, as well as to assess the safety and tolerability of the intervention.
The study will be coordinated by Hospital de Clínicas de Porto Alegre (HCPA), the sponsoring institution, while participant recruitment and data collection will be conducted at Hospital de Clínicas de Ijuí (HCI), the collaborating center.
Eligible participants will be randomly assigned to either an active stimulation group or a sham control group. Randomization will be performed using a random number sequence.
Participants assigned to the intervention group will receive transcutaneous auricular vagus nerve stimulation using the EL-30 device (NKL). The electrodes will be positioned on the left cymba conchae and the left earlobe. Stimulation will be delivered in daily 30-minute sessions throughout the hospital stay, using a pulse width of 250 μs, an intensity below the pain threshold, and alternating frequencies of 2 Hz and 15 Hz at 5-second intervals.
Participants in the control group will undergo the same procedure using the same device and electrode placement, but without active electrical stimulation. Each session will also last 30 minutes.
The intervention will begin during the postoperative period and will be administered under clinical supervision by trained healthcare professionals. Assessments will be conducted according to the study protocol, including measurements before and after stimulation sessions and at hospital discharge.
Heart rate variability (HRV) will be assessed using electrocardiography and a Polar H10 heart rate sensor. Recordings will be obtained with participants in the supine position after a 5-minute resting period, followed by 5-minute recordings.
The study will also include clinical and functional assessments during the postoperative period and at hospital discharge, according to the study protocol.
Potential risks associated with the intervention include mild discomfort, tingling, or itching at the stimulation site. Bradycardia may occur in susceptible individuals, who will be monitored during the procedure. Participants will be monitored throughout the intervention, and stimulation will be discontinued if clinically necessary.
The study will be conducted in accordance with applicable ethical standards and Brazilian regulations for research involving human participants. Written informed consent will be obtained before participation. Participant confidentiality and data privacy will be maintained throughout the study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria: Patients aged ≥18 years who are undergoing coronary artery bypass grafting (CABG), are able to understand and comply with the study protocol, and provide written informed consent
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
58 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal